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Abstract: During evaluation of skin disease treatments, dermatologists have to clinically mea-
sure the pathology severity of each patient during treatment periods. Such a process is sensitive
to intra- and inter- dermatologist diagnosis. To make this severity measurement more robust we
propose to use image processing to quantify the pathology severity. We focus on a hyperpigmen-
tation disorder called melasma. During a treatment period, multispectral images are taken on
patients receiving the same treatment. After co-registration and classiﬁcation steps, we propose
algorithms to measure the intensity, the size and the homogeneity evolution of the pathological
area. Obtained results are compared with a dermatologist diagnosis using statistical tests on a full
clinical study.
Key-words: skin, hyperpigmentation, change detection, statistical inferences, multispectral
imaging.
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Evaluation de lésions cutanées par imagerie multispectrale
Résumé : Lors de l'évaluation des traitements des maladies de peau, les dermatologues
doivent mesurer la sévérité de la pathologie de chaque patient tout au long d'une période de
traitement. Un tel procédé est sensible aux variations intra- et inter- dermatologues. Pour
rendre cette mesure de sévérité plus robuste, nous proposons d'utiliser l'imagerie spectrale. Nous
nous concentrons sur une pathologie d'hyperpigmentation cutanée appelée mélasma. Au cours
d'une période de traitement, des images multispectrales sont acquises sur une population de
patients sous traitement. Après des étapes de recalage des séries temporelles d'images et de
classiﬁcation des régions d'intérêt, nous proposons une méthodologie permettant de mesurer,
dans le temps, la variation de contraste, de surface et d'homogénéité de la zone pathologique
pour chaque patient. Les résultats obtenus sont comparés à un diagnostique clinique à l'aide de
tests statistiques réalisés sur une étude clinique complète.
Mots-clés : peau, hyperpigmentation, détection de changements, inférences statistiques, im-
ages multispectral
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1 Introduction
In dermatology, speciﬁc protocols are established to quantify the evolution of lesions severity
along a treatment period. In this report, we focus on a hyperpigmentation disorder called
melasma. This disease shows darker and irregular spots on the face caused by an abnormal
melanocytes activity in response to a hormonal reaction. Melasma has the speciﬁcity to be
symmetric in the two cheeks. Thereby, for melasma, the protocol consists in applying a studied
treatment in one cheek, and a comparator treatment in the second cheek [1]. The comparator
is often chosen as the vehicle used for the studied treatment without active product. To make
a clinical study reliable, patients are randomized [1]. The eﬃcacy of a treatment is clinically
measured by dermatologists. To this end, a clinical score is evaluated by one or several derma-
tologists in each cheek of each patient at several time moments during the treatment. Finally, a
statistical test such as the Student test [2] or the Wilcoxon test [2] is performed on these measure-
ments to obtain a quantiﬁcation of the studied treatment eﬃcacy relatively to the comparator
treatment [3]. The most widely used score for melasma severity evaluation is the Melasma Area
and Severity Index (MASI) [4, 5, 6]. It has been introduced in [7]. The MASI split the face into
4 regions: forehead, left cheek, right cheek, and chin. For each region, three scores are evaluated:
 Area (A): Measures the area aﬀected by the disease. It is estimated on a scale ranging
from 0 to 6 as: 0 = 0%; 1 ≤ 10%; 2 = 10−29%; 3 = 30−49%; 4 = 50−69%; 5 = 70−89%
and 6 = 90− 100%.
RR n° 8136
4 Prigent & Descombes & others
 Darkness (D): Color of the pathological area compared with normal skin. It is graded
on a scale from 0 to 4 as follows: 0=normal skin color without evidence of hyperpig-
mentation; 1=barely visible hyperpigmentation; 2=mild hyperpigmentation; 3=moderate
hyperpigmentation; 4=severe hyperpigmentation.
 Homogeneity (H): Homogeneity of the hyperpigmentation, graded on a scale from 0 to 4 as
follows: 0=normal skin color without evidence of hyperpigmentation; 1=specks of involve-
ment; 2=small patchy areas of involvement < 1.5 cm diameter; 3=patches of involvement
> 2 cm diameter; 4=uniform skin involvement without any clear areas).
To integrate these three criteria measured on the four regions: forehead (F), left cheek (LC),
right cheek (RC) and chin (C), the following equation is proposed in [7]:
MASI = 0.3(DF +HF )AF + 0.3(DLC +HLC)ALC
+ 0.3(DRC +HRC)ARC + 0.1(DC +HC)AC , (1)
where DF , DLC , DRC , DC are darknesses measured respectively on the forehead, left cheek,
right cheek and chin, HF , HLC , HRC , HC homogeneities measured respectively on the forehead,
left cheek, right cheek and chin and AF , ALC , ARC , AC areas measured respectively on the
forehead, left cheek, right cheek and chin. This MASI deﬁnition has been discussed in [3]. The
authors claim that the H criterion has signiﬁcant variations from one dermatologist to another.
They then propose remove the H criterion from Equation (1):
MASI = 0.3DFAF + 0.3DLCALC + 0.3DRCARC + 0.1DCAC . (2)
In this report, we propose a electronic score called diﬀerential score. The idea is to use images
with an associated image processing algorithm in order to automatically evaluate a severity
score containing area (A), darkness (D), and homogeneity (H) measurements. Such a computer
based score avoids the variability on the measures obtained by human inspection. To describe
the proposed protocol, we introduce multispectral imaging for skin analysis, present the clinical
study used for experimental results, and describe the proposed scheme.
1.1 Multispectral imaging
Multispectral images are data cubes where each slice corresponds to a monochrome image taken
at a speciﬁed wavelength. Such images allow the combination of spectral and spatial information
of the imaged area. A multispectral image can be seen as a 2D spectrocolorimeter. Several
algorithms have been proposed to analyse the spectrum of the skin, and showed that the skin
spectra contain useful information. The most popular sprectral analysis algorithm for the skin is
probably the one proposed by Stamatas et al. in [8, 9]. The authors model the skin absorbency
as a mixture of the melanin, deoxy-haemoglobin and oxy-haemoglobin components. A linear
regression associated with the Beer-Lamber law provides the proportions of the components
mentioned above for each pixel of a multispectral image. The images we use are 1200*960 pixels,
and contain 18 spectral bands with wavelengths from 405 nm to 970 nm.
1.2 Clinical study
To evaluate the proposed diﬀerential score, we use a clinical study that contains two treatments
denoted T and A. Each treatment is tested on a population of 22 patients. For each patient, one
cheek receives one of the treatments T or A and the second cheek receives a comparator that is
the vehicle used for treatments T and A. The study lasts 3 months and two multispectral images
Inria
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are taken for each patient (one per cheek) every month. Thus, we have 2 ∗ 22 ∗ 2 = 88 series of
four images corresponding to times t0 = baseline, t1 = after one month, t2 = after two months
and t3 = after three months.
1.3 Proposed methodology
To evaluate the eﬃcacy of a treatment, we need to measure the severity of the melasma on each
image taken along the clinical study. To quantify the severity for an image, we ﬁrst classify the
pathological area in the image, and then extract features describing the disease.
As we are interested in the pathology evolution, we measure change features from t0 to tk
according to the clinical protocol. Thus, the proposed scheme is drawn is Fig. 1. We ﬁrst classify
each image taken at baseline (t0). The classiﬁcation step is not described in this report. In [10]
we compare classiﬁcation methods for skin hyperpigmentation. In [11] we proposed a method
based on support vector machines with a global training and an interactive software to perform
the classiﬁcation on all the baseline images. In the second step, we extract a spectral feature
describing the studied disease. We deﬁne this feature as the linear combination of bands that
maximizes the darkness of the disease. To compute the change detection, time series of images
need to be co-registered. This is done with the algorithm described in [12] initialized by an aﬃne
registration. To evaluate the spatial changes of the disease, we propose two change detection
algorithms between monochrome images obtained by the spectral feature. These two algorithms
aim at quantifying criterion A and H, respectively. Finally, criteria calculated on the spectral
feature map and the change map give an diﬀerential score for each patient at each measurement
time. To detail the presented steps, the report is organized as follows. Section 2 describes the
spectral feature extraction method and the darkness criterion. Section 3 describes the proposed
method to quantify the changed area between t0 and tk. Section 4 proposes to use a multi-scale
change detection analysis method based on statistical inferences to get the homogeneity criterion.
Section 5 proposes an diﬀerential score from the criteria D, A and H computed in Section 2, 3
and 4. The last section concludes and discusses the proposed diﬀerential score.
Figure 1: Proposed scheme to evaluate a treatment eﬃcacy on a clinical study
2 Darkness criterion
To extract a spectral feature of the studied disease, let's assume that we have extracted a region
of healthy skin and a region of pathological skin for each series of co-registered multispectral
images. For a given patient, at a given time tk, we thus have four regions: I
pS
tk
and IhStk the
pathological and healthy regions on the cheek treated with the studied treatment, and IpCtk and
IhCtk the pathological and healthy regions on the cheek treated with the comparator treatment.
We propose to use these four regions to compute the weights of a spectral feature M deﬁned by:
M(I) =
Nb∑
b=1
mbI(b), (3)
where mb is the weight of the b
st spectral band I(b) of the image I and Nb the number of
spectral bands in the initial multispectral image. We look for features that give the highest
contrast between the healthy areas and the pathological areas.
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In the literature, feature extraction for spectral images has been widely studied. Methods of
features extraction considering a linear combination of spectral bands are PCA [13], NAPCA [14],
SVD [15], or ICA [16, 17] that tend to extract features by minimizing the correlation or higher
order statistics. The MNF approach [18] searches features by factorizing the signal matrix into
two non negative matrices. This factorization can be done by minimizing the mean square error
or the Kullback-Leibler divergence for example [19, 20]. Algorithms such as N-FINDR [21, 22, 23],
PPI [24, 25] or VCA [26] analyse the geometry of the data set in the spectral Nb dimensional
space to extract features deﬁned as extreme points in this set. We can also cite supervised
methods like DAFE [27], NWFE [28, 29] or maximum likelihood based approach [30].
2.1 Proposed methods
For skin spectral feature extraction, we focus on two approaches: one involving an objective
function optimization, and one based on independent component analysis (ICA). Before going to
these two approaches we ﬁrst introduce a normalization step that combines the four regions IpStk ,
IhStk , I
pC
tk
, IhCtk . The ﬁrst normalization combines the healthy and the pathological areas. We can
either ignore the healthy area or compute the diﬀerence between healthy and pathological areas.
We do not consider dividing healthy and pathological areas since division is more sensitive to
noise. The second normalization combines the studied treatment S and the comparator treatment
C. We use the method proposed in clinical protocols that calculate the diﬀerence S−C. Finally,
depending on the use of the healthy area we have two possible normalizations:
Detk = (µM(IpStk )
)− (µM(IpCtk )) (4)
and
Detk = (µM(IhStk )
− µM(IpStk ))− (µM(IhCtk ) − µM(IpCtk )), (5)
where Detk denotes the darkness for the patient e at tk and µM(IhStk )
(respectively µM(IpStk )
,
µM(IhCtk )
, µM(IpCtk )
) is the spatial average of the spectral featureM on the region IhStk (respectively
IpStk , I
hC
tk
, IpCtk ).
2.1.1 Objective function
In this section, we propose an objective function that maximizes both the distance between
pathological and healthy areas, and the deviation between measurement times. The distance
between healthy and pathological areas can be measured by a diﬀerence to avoid noise introduced
by divisions. Thus, the objective function is:
f =
Nb∑
b=1
mb
{
tn∑
t=t1
Ne∑
e=1
[
µIe,hSt0
− µIe,pSt0
− µIe,hCt0 + µIe,pCt0
− µIe,hSt + µIe,pSt
+µIe,hCt
− µIepCt
]}
. (6)
The function f is linear with respect to the parameters mb of M . The optimization is then
trivial. The solution is the spectral band with the highest contrast if we consider only positive
mb. If we consider also negative mb, the solution is given by two bands. These solutions are
optimal with respect to the darkness criterion.
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Figure 2: Feature obtained by ICA on all the images at t0 on a clinical study of melasma. X-axis:
indexes of spectral bands, Y-axis: coeﬃcient given to spectral bands.
2.1.2 ICA-based method
In this section we propose to use ICA to get a spectral feature of melasma. Performing ICA on
a multispectral image gives, at most, as many features as the number of bands in the image. We
then select the most representative feature of the pathological area. The selected component is
the one that maximizes the deviation between a healthy reference area and the pathological area
of interest. If we calculate ICA separately on all the images we get slightly diﬀerent features from
one images to another. On Fig. 2 one can see that features obtained in all the images of a clinical
study have similar shape. Several features are negative due to the ICA model indetermination.
To get a single feature for all the images, we propose to calculate the average feature with a −1
coeﬃcient for the negatives features. It can be noticed that the coeﬃcients in the near infra-red
(IR) bands are negative. During experiments we observe that this near infra-red information
biased the contrast measurements. The IR coeﬃcients for the ICA based feature are then set to
zero.
2.2 Obtained results
Proposed feature extraction methods have been tested in a clinical study involving three active
treatments that we denote St, Ad1 and Ad2. Clinical conclusions state that St has no eﬃcacy
whereas Ad1 and Ad2 have eﬃcacy. Furthermore, Ad2 has a stronger eﬀect than Ad1. The
protocol of this study is the same as the one presented in section 1.2.
We calculate a spectral feature for each treatment St, Ad1 and Ad2 individually. Then we
compute the features in all the images of the study on the four regions IpStk , I
hS
tk
, IpCtk , I
hC
tk
manually segmented. It results in a darkness measurement Detk for each patient. We ﬁnally
apply a Wilcoxon hypothesis test for each treatment between tk and t0 to get a quantiﬁcation
of the treatment eﬃcacy. Table 1 shows the p-values obtained by the Wilcoxon test with the
proposed methods and with the luminance feature that we use as a reference feature. Equation (5)
is used for normalization. As one can see, all the features agree with the clinical conclusions.
The diﬀerence is in how fast features detect an eﬃcacy of the treatment. The method based
on the objective function optimization gives the fastest eﬃcacy detection compared to the ICA-
based method and the luminance. To understand these diﬀerences, we plot the features obtained
with all the methods in Fig. 3. As the luminance coeﬃcient is not linear, we use its linear
approximation Y . We observe that the feature obtained by f selects a speciﬁc band at 590 nm
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Figure 3: Spectral features obtained by the studied methods. X-axis: wavelengths in nano-
meters, Y-axis: coeﬃcients mb.
Table 1: Results obtained by the Wilcoxon test on a clinical study with the normalization of
Equation (5) for the darkness criterion.
Feature Traitement t1 − t0 t2 − t0 t3 − t0
L
St 7.959 10
−1 5.014 10−1 7.173 10−1
Ad1 3.793 10
−1 1.128 10−2 8.793 10−2
Ad2 9.798 10
−2 3.204 10−3 5.312 10−4
f
St 1.476 10
−1 1.089 10−1 7.563 10−1
Ad1 5.571 10
−2 3.400 10−2 4.373 10−2
Ad2 8.360 10
−3 3.204 10−3 9.350 10−4
ICA
St 5.349 10
−1 8.767 10−1 9.176 10−1
Ad1 4.080 10
−1 2.987 10−2 9.798 10−2
Ad2 7.873 10
−2 5.233 10−3 9.350 10−4
for the treatments St, and Ad2 and the band 645 nm for the treatment Ad1. ICA selects spectral
bands mainly around 600 nm, but sets signiﬁcant coeﬃcients to wavelengths between 400 and
600 nm. The Y feature selects bands in the 500-600 nm wavelengths. Due to the Stamatas et
al. model for pigmentation we should focus on the wavelength between 600 and 700 nm. Thus,
heigh coeﬃcients in the spectral ranges out of 600-700 nm explain why the ICA based method
and the Y features detect later the treatments eﬃcacy than the feature estimated by f . Table 2
shows the results obtained with the Wilcoxon tests on the same studies with the normalization
of Equation (4). The results are comparable to the ones with the normalization of Equation (5).
This means that the calibration of the camera is robust and that the normalization with the
healthy area is not mandatory. As this healthy normalization can introduce noise due to the
variation of the healthy area, we prefer to use the normalization of Equation (4). To validate
the spectral features calculated on the test clinical study, we apply them on the validation study
described in section 1.2. The p-values of the Wilcoxon tests on the validation study are shown in
Table 3. For f we choose the feature b590 − b405. Obtained results are coherent with the clinical
analysis.
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Table 2: Results obtained by the Wilcoxon test on a clinical study with the normalization of
Equation (4) for the darkness criterion.
Feature Traitement t1 − t0 t2 − t0 t3 − t0
L
St 7.959 10
−1 6.791 10−1 6.416 10−1
Ad1 1.306 10
−2 2.289 10−2 9.798 10−2
Ad2 1.788 10
−1 7.169 10−3 1.918 10−3
f
St 7.173 10
−1 5.349 10−1 5.014 10−1
Ad2 2.289 10
−2 1.737 10−2 3.400 10−2
Ad3 1.997 10
−2 1.609 10−3 9.725 10−3
ICA
St 6.416 10
−1 5.694 10−1 5.014 10−1
Ad1 1.997 10
−2 3.400 10−2 8.793 10−2
Ad2 1.476 10
−1 7.169 10−3 1.123 10−3
Table 3: Results obtained by the Wilcoxon test on the validation clinical study for the darkness
criterion.
Test Treatment t1 − t0 t2 − t0 t3 − t0
L
A 8.455 10−1 7.210 10−1 1.270 10−1
T 9.741 10−1 9.397 10−3 1.637 10−3
f
A 1.116 10−1 5.373 10−1 9.777 10−2
T 4.750 10−1 3.859 10−3 9.337 10−3
ICA
A 7.210 10−1 5.589 10−1 1.627 10−1
T 8.966 10−1 6.389 10−3 3.478 10−3
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3 Area criterion
To calculate an area criterion, we propose to compute the spatial changes between tk and t0.
Lets denote Cet0 a classiﬁcation mask at t0 for the patient e obtained by the method proposed
in [31]. We denote by Betk/0 a binary change map between t0 and tk for the patient e. Then, the
area criterion can be calculated by:
Aetk/0 =
card{x : Betk/0(x) = 1}
card{x : Cet0(x) = 1}
. (7)
In the literature, numerous methods have been proposed to quantify the changes between two
images. Two state of the art articles are [32, 33]. Change detection methods consider the image
either globally by subtraction or division [33, 34, 35, 36] or locally with a window that browses
the image [37, 38, 39, 40, 41, 42].
Using a local window tends to a loss of resolution. Furthermore, the procedure of dividing
images is sensitive to noise. That is why, we choose to perform change detection by subtraction:
F etk/0 = M(I
e
tk
)−M(Iet0), (8)
where M(Ietk) (respectively M(I
e
t0)) is a gray scale image obtained by integrating the spectral
image Ietk (respectively I
e
t0) with the spectral feature M . A threshold τ on F
e
tk/0
allows to get
the binary change map:
Betk/0(x) =
{
1 if F etk/0(x) > τ and C
e
t0(x) = 1
0 otherwise
(9)
where x denotes the position of any pixel in the image. The choice of τ is crucial. We propose
a method that computes one threshold τ per image series estimated on the histogram of F et1/0 .
First, we assume that the histogram of F et1/0 is monomodal symmetric and centred in zero in the
case of no changes F etk/0 . This assumption is justiﬁed since F
e
t1/0
is a centred noise in zero in the
case of no changes. Then, we assume that there are no signiﬁcant changes in the negative part
(i.e. the disease does not become worst). Thus, in the case of no disease decreasing, the number
of positive and negative pixels in F et1/0 should be the same. With this model, the area of changes
in F et1/0 is A =
(]>0)−(]≤0)
(]>0)+(]≤0) , where (] > 0) (respectively (] ≤ 0)) denote the number of positive
(respectively negative) pixels in F et1/0 . To calculate τ from F
e
t1/0
, we sort the positive pixels of
F et1/0 and take the threshold τ such as: (] > 0 and < τ) = (] ≤ 0).
An inconvenience of thresholding methods for change detection is their sensitivity to noise. To
decrease noise, we ﬁlter the change map Betk/0 with opening and closing mathematical morphology
operators using a disk of two pixels as a structural element. Fig. 9 d-f) shows obtained results
for an image time series. For this patient, dermatologists clinically measure a decrease of the
pathology. As one can see, the area measured by the algorithm shows a signiﬁcant evolution at
time t1 and then a gradual evolution of the pathological area. To validate this area measurement,
we calculate change areas Aetk/0 for all the patients of the validation clinical studies. As for the
darkness measurement, we compute the Wilcoxon test for each treatment between tk and t0 in
the areas measurements. Results are shown in Table 4. Results show that the treatment T
has an eﬀect whereas the treatment A does not. This is in agreement with the dermatologists
diagnosis.
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Table 4: p-values of the Wilcoxon tests on the validation clinical study for the area criterion.
Criterion Treatment t1 − t0 t2 − t0 t3 − t0
Area
A 2.840 10−1 3.986 10−1 1.045 10−1
T 4.552 10−1 3.478 10−3 2.438 10−4
4 Homogeneity criterion
With the proposed darkness (section 2) and area (section 3) criteria, we obtained a deﬁnition
of a diﬀerential score with two components D and A like in the clinical MASI deﬁned in [3]. In
this section we study a diﬀerential and numerical equivalent of the homogeneity clinical criterion
proposed in [7]. This criterion jointly measures the distribution and the size of brown areas con-
stituting the pathology area. To get such information, we adapt the methodology of Statistical
Parametric Mapping (SPM) [43] developed for functional MRI. This approach models a change
map as a Gaussian random ﬁeld. Then a multi-scale analysis partition this map into regions
and a probability is assigned to each region. These probabilities measure the likelihood for the
regions to be a realization of the random ﬁeld. For our application, we apply this methodology
on each change map F etk/0 . To model F
e
tk/0
as a Gaussian random ﬁeld, we need to normalize it.
Then we apply the multi-scale analysis to get regions and calculate probabilities.
4.1 Change map normalization
First, we smooth the image F etk/0 with a Gaussian convolution ﬁlter to increase its spatial cor-
relation. Second, as the interest area of F etk/0 comes from a unique class, its histogram can
be modelled as monomodal in the hypothesis of no changes. We use a histogram speciﬁcation
to transform it into a Gaussian distribution. We center and reduce the speciﬁed histogram to
standardize it. In the following we will denote FNetk/0 the normalized change map.
4.2 Change map thresholding
FNetk/0 satisﬁes the conditions to apply the Gaussian ﬁeld theory [44]. An interesting characteristic
of a Gaussian ﬁeld F of size S is the DT (Diﬀerential Topology) characteristic deﬁned by:
χ(Au) = (−1)(d−1)
d−1∑
k=0
(−1)kχk(Au) (10)
with
Au = {s ∈ S, F (s) ≥ u}, (11)
where u is a given threshold, d the dimension of the ﬁeld and χk(Au) the number of points s ∈ S
satisfying the conditions: (a) F (s) = u, (b) F (i)(s) = 0,∀i ∈ [1, d − 1], (c) F (d)(s) > 0 and (d)
the (d − 1) × (d − 1) matrix of second order partial derivatives of F(s) has exactly k negative
eigenvalues. In the above expression, F (i) denotes the ith derivative of F . In the 2D case (i.e.
d = 2), for a given threshold u the expectation of the DT characteristic of a centred and reduced
Gaussian ﬁeld can be written as follows [44]:
Eχ(Au) = S(2pi)
3
2 |Λ| 12σ−3ue− u
2
2σ2 (12)
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with S the surface of the ﬁeld, Λ the 2 × 2 correlation matrix of the ﬁeld derivatives, and
σ2 = E(F 2).
In order to estimate the likelihood of a pixel of FNetk/0 and its neighbourhood under the Gaussian
ﬁeld assumption, we compare its characteristic at a threshold u with the DT characteristic. Two
parameters can be used to compute this likelihood: the maximum intensity and the spatial extent
of the considered neighbourhood above u.
Let x0 denotes the maximum intensity of R
x0
u a region above the threshold u. The likelihood
of this region under the Gaussian ﬁeld assumption is [45]:
P (Rx0u ∈ F ) =
Eχ(Ax0 )
Eχ(Au)
=
x0
u
e
u2−x20
2 . (13)
Let S0 denotes the spatial extent of R
S0
u a region above the threshold u. The expectation for
this region under the Gaussian ﬁeld assumption is [45]:
E(RS0u ∈ F ) =
E(Nu)
Eχ(Au)
, (14)
where E(Nu) is the expectation to have Nu pixels above the threshold u in a Gaussian random
ﬁeld F . As F follows a standard normal distribution,
E(Nu) = S
∫ ∞
u
(2pi)
1
2 e−
x2
2 = SΦ(−u) (15)
then,
E(RS0u ∈ F ) =
Φ(−u)
(2pi)
3
2 |Λ| 12ue−u22
. (16)
Thus, the number of pixels in a region above the threshold u has an exponential distribution
with the parameter λu = 1/E(RS0u ∈ F ). We can then write the probability of a region RS0u to
appear in a realization of the Gaussian ﬁeld by:
P (RS0u ∈ F ) = e−λuS0 = e
(2pi)
3
2 |Λ|
1
2 S0ue
−u2
2
Φ(−u) (17)
Finally, for a spatial region above u with the maximum intensity x0 and the spatial extend
S0, its probability to be in F is [45]:
P (Rx0,S0u ∈ F ) = min(P (Rx0u ∈ F ), P (RS0u ∈ F )). (18)
Thereby, to detect changes between t0 and tk we deﬁne a family of nu thresholds U =
{u1, ..., unu}. For each ui, F etk/0 is segmented into regions denoted Rxo,S0ui . This segmentation is
obtained by a connected components analysis of the class deﬁned by the pixels of F etk/0 above
the threshold ui. Then we assign a probability P (R
xo,S0
ui ∈ F ) to each region Rxo,S0ui . This
process gives a statistical map of the changes denoted SMetk between t0 and tk. The algorithm 1
summarizes the procedure for obtaining SMtk between I0 and Ik for a given patient.
4.3 Final normalization
The statistical approach proposed in Section 4.2 makes the hypothesis that changes are rare
events. In our images, a large part of the pathological area can change. Thus, if we apply
directly the methodology describes above, we will detect only a small part of the changes (see
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Algorithm 1 Multi-scale analysis
Require: I0, Ik, Mp0
1: F etk/0 = Ik − I0
2: Smooth and normalize F etk/0 to get F
Ne
tk/0
(see section 4.1)
3: Choose a family U = u1, ..., unu
4: for i = 1 to nu do
5: Compute the connected components above ui
6: for each connected component do
7: Calculate P (Rx0,S0u ∈ F ) with eq. 18
8: end for
9: end for
10: Merge the obtained connected clusters obtained with the family U to get SMetk
ﬁgure 9 g-i)). Homogeneity variations cannot be quantiﬁed in these maps. We propose then to
introduce the normalization:
FNdetk/0 = F
Ne
tk/0
+
1
Nr
tk∑
r=t0
(
µCt0 (F
Ne
tr/0
)− µCt0 (FNet1/0)
)
(19)
where Nr is the number of time measurements between t0 and tk. µCt0 (F
Ne
tr/0
) (respectively
µCt0 (F
Ne
t1/0
)) denote the average of the pixels intensities in the interest area of FNetr/0 (respectively
FNet1/0) delimited by Ct0 . If the normalized data with Equation (19) do not respect the rare event
hypothesis, the calculated statistics will be biased. Nevertheless, we do not use the absolute
values of these statistics but their spatial repartition. Fig. 9 j-l) shows SMetk cartographies
obtained with the normalization of Equation (19). The pathology evolution is now visible during
the time sequence.
To quantify a treatment eﬃcacy from homogeneity maps, we integrate them into a scalar
criterion. To do so, we deﬁne a function fes (p) that represents the spatial repartition of the
changes by:
fes (p) =
card{x : SMetk(x) ≤ p}
card{SMetk}
. (20)
fes (p) is an increasing function from [0, 1] to [0, 1]. As the interpretation of f
e
s (p) is not straight-
forward, we prefer to work with fpetk (s) that is the inverse function of f
e
s (p). A linear interpolation
is used to calculate fpetk (s) with a regular sampling along s. f
pe
tk
(s) is also an increasing function
from [0, 1] to [0, 1]. In the following, we use fpetk (s) for both calculating a graphical representation
of the homogeneity criterion (see section 5), and a scalar Hetk describing the homogeneity of the
patient e at time tk.
To integrate fpetk (s) in a scalar H
e
tk
∈ [0, 1], we can compute:
Hetk = 2
∫ 1
0
|fpetk (s)− s|ds. (21)
Hetk represents the area between the function f
pe
tk
(s) and the identity function Id(s) = s. Id
corresponds to the most heterogeneous repartition that can be expected. Then, more homoge-
neous changes yield higher values Hetk . To calculate H
e
tk
with discrete data, we use the Riemann
integral.
To validate the proposed homogeneity criterion, we apply it on the validation study. The
homogeneity measure makes sense only when some changes appear in the image between t0 and
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Figure 4: Time sequences of the homogeneity measurements for the patients of the group where
an evolution has been measured by the area and darkness criteria. X-axis: time in weeks (t0 = 1,
t1 = 4, t2 = 8, t3 = 12), Y-axis: homogeneity value.
tk. A margin is then ﬁxed at 10% of the pathological area changes below which we do not consider
the criterion Hetk . To qualitatively evaluate the homogeneity criterion, we plot its evolution for
the population of patients whose pathology evolve. Due to the darkness and the area criteria,
the considered patients are those who receive the treatment T in the validation study. Fig. 4
shows time plots of the homogeneity measurement for each patient of the group receiving the
treatment T . If the treatment has an eﬀect, we expect to see the homogeneity measurement
growing. In this population of 22 patients, we observed that for only 7 patients the H criterion
is not interpretable. Indeed, for ﬁve patients less than 10% of the pathological area changes at
time t2 = 8 or t3 = 12 and for two patients there were less than 10% of the pathological area that
change in all the time sequence. For the others ﬁfteen patients we globally observe the expected
growth of the homogeneity with time. For most patients (in blue) main changes occurred in
the second measurement time t1 = 4, and for 4 patients (in red), main changes occurred in
time t2 = 8. These results show that the homogeneity criterion gives relevant interpretation
of disease progression during treatment. This criterion is interpretable only on patients whose
pathology has evolved. This is why we recommend to use Hetk as an extra criterion to analyse
the evolution of a patient pathology.
5 Graphical representation
The clinical MASI as described in [3] and [7] calculates a linear combination of darkness, area and
homogeneity measurements (see Equations (1) and (2)). For the diﬀerential score, such linear
combination does not have any meaning. Indeed, the three criteria have diﬀerent dynamics,
and combining them can bias the ﬁnal measurement. That is why we prefer to keep the three
measurements independent. To make the diﬀerential score easily readable for an individual
patient we propose the following graphical representation using colored bars.
5.1 Darkness representation
The proposed darkness criterion is a diﬀerential measure between two monochrome images. Its
theoretical magnitude is then [−255, 255] for 8 bits images. In the experiments, we observe that
the interval is [−12, 12]. To make a graphical representation of D, we use a function to transform
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Figure 5: Plot of the darkness transformation of Equation (22). X-axis: D in the scale values
[-255, 255], Y-axis: DG values in the scale [0,1] .
(a) (b) (c)
Figure 6: Darkness graphical representation. a) for a patient whose pathology became darker,
b) for a patient with stationary darkness, c) for a patient whose pathology decrease.
the maximum of dynamic from the interval [−12, 12] into the interval [0, 1]:
DG =
D√
1 +D2
(22)
where DG is the darkness value used for the graphical representation. Fig. 5 shows a plot of the
function of Equation (22). The darkness bar contains a chip with a color from red (-12) to blue
(+12). This chip position on the bar depends on the DG value from -12 to 12. Fig. 6 shows
three examples of darkness representation bars.
5.2 Area representation
The area criterion we proposed has values in the interval [0, 1]. The graphical representation we
choose is then a percentage bar. Fig. 7 shows examples of graphical representation of the area
criterion.
(a) (b) (c)
Figure 7: Area graphical representation. a) for a patient with stationary pathological area, b)
for a patient whose pathological area decrease by 26%, c) for a patient whose pathological area
decrease by 86%.
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(a) (b) (c)
Figure 8: Homogeneity graphical representation. a) for a patient with without evolution of the
pathology, b) for a patient with heterogeneous variation of the pathology, c) for a patient with
homogeneous variation of the pathology.
5.3 Homogeneity representation
For the graphical representation of the homogeneity criterion, we propose to use fpetk (s). In fact
this information is richer than Hetk . The graphical bar of homogeneity is then a plot of f
pe
tk
(s)
with a gradient color. Values of fpetk (s) close to zero are in blue and values of f
pe
tk
(s) close to one
are in red. Intermediate values are represented with the jet colormap. If the gradient is all
red, that means there is no homogeneity variation. The slower the gradient changes from blue
to red, the more heterogeneous the variation is. Fig. 8 shows examples of the homogeneity bar.
5.4 Diﬀerential score representation
Finally, the diﬀerential score representation is the combination of the three bars of darkness,
area and homogeneity. An example for a patient whose pathology decrease is shown in Fig. 9
and an example for a patient whose pathology does not decrease is shown in Fig. 10. As one can
see, with this graphical representation, we can both quantify and qualify the patient pathology
evolution.
6 Conclusion
In this report, we proposed a strategy to calculate the severity of skin hyperpigmentation using
multispectral images. The proposed criterion called diﬀerential score has been developed to be
a computer score related to the clinical MASI criterion. The proposed diﬀerential score has been
tested on a full clinical study and gave relevant results with the clinical analysis. The proposed
methodology does not take into account any speciﬁcity of the studied pathology. We can thus
adapt it to other pathologies like vitiligo, scars or rosacea.
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